Canadian Biotech Takes COVID-19 Nasal Spray To Asia Via Glenmark

Eyes On Effectiveness Against Variants

Glenmark hopes to launch SaNOtize’s nitric oxide nasal spray for COVID-19 in India by the fourth quarter of 2021 post Phase III trials, as part of wider deal that covers other Asian markets. Can the self-administered product impact market dynamics positioned as the first line of defense against COVID-19?

partnering
SaNOtize-Glenmark Partner For COVID-19 Nasal Spray • Source: Alamy

The Vancouver, Canada-based biotech firm SaNOtize Research and Development Corporation has delivered on its intent for an India-based alliance, now sewing up an exclusive long-term deal with Glenmark Pharmaceuticals Limited to manufacture, market and distribute its novel Nitric Oxide Nasal Spray (NONS) for COVID-19.

Glenmark will commercialize NONS in India and certain other Asian markets including Singapore, Malaysia, Hong Kong, Taiwan, Nepal, Brunei, Cambodia,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip